Please assess the completion status of the following clinical trial:

Trial Title: Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Residing in the community for at least three months;~2. Eligible to receive all three agents according to standard MDA criteria~Exclusion Criteria:~1. Not eligible to receive one or more drugs according to standard MDA criteria;~2. Less than 5 years of age (not eligible for ivermectin)\*\*~3. Pregnant women (azithromycin only, not eligible for albendazole and ivermectin)~4. Lactating women (Only administered azithromycin and albendazole, not eligible for ivermectin)\*\*~5. History of allergies to the drugs being studied (azithromycin, ivermectin, albendazole)~6. Residents who cannot swallow tablets~   * Note that patients that are not eligible for IVM, will receive azithromycin and albendazole. Patients that receive azithromycin and albendazole will be followed up through the same procedure as the triple drug therapy to try to track any AEs attributed to the two drug combination.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Separate Administration (Type: ACTIVE_COMPARATOR): Standard administration of Albendazole/Ivermectin separated from administration of azithromycin
- Co-administration (Type: EXPERIMENTAL): Combined administration of Albendazole/Ivermectin/Azithromycin at a single time point

Based on this trial design, predict the completion outcome and termination type (if applicable).